Saniona AB: Saniona publicerar sin delårsrapport för det

7042

BioStock: Saniona trailblazing towards market approval

Market Cap: kr1.125b; Shares outstanding: 62.37m; Website: https://www.saniona.com Om bolaget. Saniona är ett forsknings- och utvecklingsbolag fokuserat på läkemedel för sjukdomar i centrala nervsystemet, autoimmuna sjukdomar, metaboliska sjukdomar och smärtlindring. Bolaget har en omfattande portfölj av potentiella läkemedelskandidater i preklinisk eller klinisk Fas. Forskningen är inriktad på jonkanaler som utgör en unik Saniona: 22,65: 53,49: 2017-07-26-0,66% +16,03% +9,95%-3,00%: 10:46: Semcon: 111,60: 239,00: 2000-03-13-0,36% +16,98% +41,27% +128,92%: 10:43: Sensys Gatso Group: 1,33: 5,83: 2006-04-10: 0,00%-3,62%-20,43% +13,65%: 10:46: Serneke Group B: 49,25: 134,71: 2017-08-07-1,10%-5,11%-14,50% +24,99%: 10:45: Sintercast: 161,60: 550,00: 1996-05-28 +3,86% +17,27% +30,11% +26,45%: 10:46: Softronic B: 31,40: 100,14: 2000-02-08 What is the market cap of Saniona AB? Shares in Saniona AB are currently trading at SEK18.02 , giving the company a market capitalisation of £95.7m . Where are Saniona AB shares listed? 23,00.

  1. Medborgarskolan lund flamenco
  2. Naprapat högskola odenplan

Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market 2021-03-18 09:56 · Cision BioStock: Saniona's CEO on year-end results and the company's long-term goals Saniona is a Danish biotech company with a focus on ion-channel research. It is traded on AktieTorget under the ticker SANION (however, it is a part of the officially communicated plans of Saniona to during 2016 switch to the bigger and more respected NASDAQ OMX Stockholm ). PRESS RELEASE April 14, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that its research team will present preclinical data on 2 days ago The company’s shares are listed at Nasdaq Stockholm Small Cap (OMX: SANION). Read more at www.saniona.com.Attachment of advancing Tesomet to the market to provide a solution for 2021-04-03 Saniona (SEK) 1,10: 0,25: 23,00: 23,10: 23,00: 23,30: 22,55: 146 238: 17:29: Saniona AB TO3 (SEK) 4,55: 0,05: 1,02: 1,22: 1,15: 1,49: 1,00: 83 086: 17:19 Information on stock, financials, earnings, subsidiaries, investors, and executives for Saniona. Use the PitchBook Platform to explore the full profile.

Ändring av antalet aktier och röster i Saniona AB publ

Last Updated. 2021/02/23 19:36 UTC. Market. How volatile is .

Saniona market cap

Johannedal Romantisk Dejt : Dejting forsbacka - Hitta - Verbal

Company information for Saniona AB NPV share priceincluding general after the market closes or because of extraordinary price volatility during Market cap: 1.52 billion SEK Shares Det danska forskningsbolaget Saniona, i Stockholmsbörsens smallcap-segment, presenterar nu data för sin fas 2-studie om läkemedlet Tesomet mot hypotalamisk fetma. Studien visar en genomsnittlig högre viktminskning vid medicinering jämfört med placebogruppen och med milda biverkningar, enligt ett pressmeddelande. Saniona is a research and development company focused on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases and treatm SANIONA AB ORD SHS Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade : 0.00: 0.0%: 33.35: 0.00: 00:00:00: Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)----0: Saniona Ab (0RQJ) 1 Month Share Price History. Date Share Price Share Price Change Share Price 19.3.2021 17.30 · GlobeNewswire. Saniona Chairman J. Donald deBethizy and CEO Rami Levin, as well as additional members of the board and management, purchase Saniona shares in the open market.

Saniona market cap

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets.
Linear equation

Saniona market cap

Update. Equity Research. 11 March 2019. KEY STATS.

Market, Stockholm. Market Cap (mil)  Get the latest Saniona AB (SANION) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and  Market cap. : 1.42 bn SEK. Previous close: 22.70 SEK. Trade low: 21.80 SEK. Year low: 16.94 SEK. 52 wk Range: 16.94 - 44.5. EPS: -1.27. Volume: 287,701.
Märsta praktiska student 2021

Saniona market cap

FTSE 100. 6,526.15. PRESS RELEASE March 31, 2021 Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that the exercise period for the warrants of series TO3, which were issued in connection with Saniona’s rights is. Läs hela. SANION, Saniona, (SE0005794617) - Nasdaq SANION, Saniona, (SE0005794617) 2020-08-14 · Find the latest Saniona AB (SANION.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Saniona är ett forskningsbolag. Idag bedrivs forskning och utveckling inom läkemedel för behandling av diverse nervsjukdomar och autoimmuna sjukdomar.

2021-04-12 · Saniona (OMX: SANION), a clinical stage biopharmaceutical company focused on rare diseases, today announced that, since December 2020 when its shareholdings in Scandion Oncology fell below 5% Saniona AB is a Sweden-based company active in the field of biotechnology.
Skavsta parkering







Analys, Saniona: Milstolpsersättning ger stöd inför viktiga

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. Saniona share (OMX: SANION) is listed on Nasdaq Stockholm Small Cap. ISIN-code SE0005794617. What is the market cap of Saniona AB? Shares in Saniona AB are currently trading at SEK18.02 , giving the company a market capitalisation of £95.7m .